Marco Meglio

Students share their experience in the virtual classroom, navigating new requirements, and the lessons learned from their position in a global pandemic.

Patients treated with the GammaSense neuromodulation therapeutic also demonstrated a significant 61% reduction in whole brain atrophy and volumetric loss associated with Alzheimer disease.

Future analysis evaluating the optimal candidate for disease and duration of treatment for the use of tofacitinib in autoimmune encephalitis is needed, according to the study authors.

The assistant professor of neurology at Mayo Clinic detailed the areas of autoimmune encephalitis research that need more attention, as well as the diagnostic potential of autoantibody assays.

Treatment with masitinib was shown to prevent the amyloid-induced hemichannel-dependent mast cell activity in bone marrow-derived mast cells and brain mast cells.

The director of the Institute for Health, Health Care Policy and Aging Research at Rutgers University discussed a recently published report on meeting the challenge of caring for persons with dementia and their care partners and caregivers.

The disposable NeuroCap allows for minimal chances of flawed EEG due to all of the contact points between scalp and electrode sensors being pre-gelled.

Increases in reperfusion treatment were the largest in lowest-volume hospitals, among rural residents, and among patients aged 85 years and older.

Patients having a relapse, confirmed disability accumulation, or worsening in fatigue had significant negative impact on each of the work productivity and activity impairment measures.

At 18-month follow-up, 70% of those with an advanced Alzheimer disease pattern had 1 point or more increase in CDR-SB, an event predefined as clinically meaningful deterioration.

The assistant professor of neurology at Mayo Clinic discussed his presented talk at ACTRIMS Forum 2021 on autoimmune encephalitis.

The duo from Cleveland Clinic discussed the reasons for choosing cycling as part of their newly initiated clinical trial, as well as what has been observed for home-based exercise interventions.

Genetically-index TNF-TNFR1 signaling blockade predicted reduced risk of Crohn disease and ulcerative colitis, and increased multiple sclerosis risk.

Protalix BioTherapeutics intends to report final data on the agent, also known as PRX-102 in the second half of 2021, as well as present those findings at an appropriate medical conference.

The clinical research coordinator at Massachusetts General Hospital discussed his presentation from ACTRIMS 2021 on electronic pill bottle monitoring to promote MS medication adherence.

The recommendation stems from recently published topline data which demonstrated a clinically meaningful treatment response compared to placebo but failed to meet statistical significance.

The authors expanded upon the notion that nonadherence to oral DMTs is more nuanced than simply missing doses.

The authors noted that future studies evaluating the time course of fatigue in patients with multiple sclerosis are needed.

Higher concealment behavior for patients with multiple sclerosis was associated with higher anxiety, but not depression.

The authors concluded that longitudinal optical coherence tomography measures may be sensitive to changes in cognitive function and may be useful for monitoring neuroprotective therapies.

The authors concluded that this approach may be applied in fatigue management treatment protocols, without increasing symptoms, in patients with multiple sclerosis.

The effect of cladribine on CD8+ T lymphocytes varied by age, with steady increases shown in the younger population whereas there were fluctuations observed in the older group.

Tavapadon’s rare combination of efficacy and minimal adverse effects may indicate a step forward in the treatment of Parkinson disease.

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical provided his expectations for the upcoming ACTRIMS Forum.

The duo from Cleveland Clinic discussed their recently initiated study which will evaluate the neuroprotective features of home-based intervention in high-risk individuals for Alzheimer disease.

Factors such as previous emergency department visits, hypertension, and tobacco use disorder were related to future migraine-related emergency department visits.

Investigators noted that empirical work is needed to determine if change from baseline, fixed time point assessments, and responder definitions, or other approaches optimize power and sensitivity to change.

The breakthrough designation gives BrainQ access to the new Medicare Coverage of Innovative Technology pathway.

Overall, variants within known ALS-linked genes are of potential clinical importance for 42% of patients, according to the study authors.

Investigators identified no additional benefit nor harm from the use of low-dose alteplase to treat patients with lacunar acute ischemic stroke compared to other subtypes of AIS.